Table I.
Baseline characteristics of participants with and without PAD
| Overall (N = 959) |
Subjects with PAD (n = 172) |
Subjects without PAD (n = 787) |
P | |
|---|---|---|---|---|
| Demographic data | ||||
| Age (y), mean* | 63 ± 9 | 65 ± 8 | 62 ± 9 | .0005 |
| Men/women (%) | 71/29 | 74/26 | 71/29 | .4232 |
| Body mass index (kg/m2), mean* | 30 ± 6 | 29 ± 5 | 30 ± 6 | .0167 |
| Systolic blood pressure* | 133 ± 15 | 133 ± 15 | 133 ± 15 | .9834 |
| Diastolic blood pressure* | 78 ± 9 | 76 ± 10 | 78 ± 9 | .0163 |
| Heart rate* | 67 ± 11 | 68 ± 12 | 67 ± 10 | .0736 |
| Risk factors (%) | ||||
| Diabetes† | 49 | 35 | 52 | <.0001 |
| Hypertension | 74 | 75 | 74 | .7697 |
| Dyslipidemia | 61 | 65 | 60 | .2871 |
| Current smoking | 14 | 19 | 13 | .0265 |
| Medical history (%) | ||||
| CHD | 54 | 61 | 52 | .0163 |
| PAD | 18 | 100 | 0 | |
| Stroke or transient ischemic attack | 6 | 12 | 5 | .0007 |
| No documented vascular disease‡ | 39 | 0 | 48 | |
| Concomitant medications (%) | ||||
| Antiplatelet | 83 | 84 | 82 | .4287 |
| Atorvastatin | 100 | 100 | 100 | |
| ACE inhibitor or ARB | 68 | 67 | 68 | .9136 |
| β-Blocker | 48 | 50 | 48 | .6418 |
| Thiazolidinedione | 10 | 8 | 10 | .4255 |
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker.
*
Presented as arithmetic mean ± SD.
†
Denotes diabetes requiring pharmacotherapy.
‡
Refers to patients with Framingham Risk Score >20%.